Viking Therapeutics announced the initiation of a Phase 2 clinical trial of VK2735, the company’s wholly-owned dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors. VK2735 is in development for the potential treatment of various metabolic disorders such as obesity. The Phase 2 VENTURE trial is a randomized, double-blind, placebo-controlled study that will evaluate the safety, tolerability, pharmacokinetics, and weight loss efficacy of four different doses of VK2735, administered subcutaneously, once weekly.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VKTX:
- Viking Therapeutics call volume above normal and directionally bullish
- Roth sees positive readthrough to Viking Therapeutics from Novo data
- Viking Therapeutics files automatic mixed securities shelf
- Viking Therapeutics reports Q2 EPS (19c), consensus (19c)
- Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update